MAZE·Maze Therapeutics, Inc.
MAZE|Analyst Targets
MAZE|Insider Trading
MAZE|Fundamentals
MAZE|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-0.79 | - | - |
| Q3'25 | $-0.69 | $-0.66 | +4.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0 | - | - |
| Q3'25 | - | $0 | - |
MAZE|Monthly Returns
Market Data
MAZE Stock Snapshot
- Market cap
- 1.85B
- Day range
- $29.00 – $35.00
- News sentiment
- 74/100 · Bullish
- Analyst target
- $62.54 (+81.3%)
- Consensus
- Buy · 22 analysts
MAZE is on the weaker side of its setup, with little confirmation for a reversal yet. Company-specific news dominates here; sector-level flows matter less than for larger names.
Behaviour On Record
What MAZE's own history says about today's numbers
- Realized volatility (21d)
- 56.9% 39th pct
Maze Therapeutics, Inc. is currently running 56.9% annualised volatility over the last 21 sessions. Measured against MAZE's own 2 years of daily returns rather than a market-wide average, that is the 39th percentile — on the quiet side for this stock, against a typical reading of 63.4%.
Overnight risk is measurable too: MAZE has opened more than 2% away from the prior close in 103 of 442 sessions (23.3% of the time), with the largest gaps running +31.2% and -22.8%.
All figures computed from 443 daily closes between 2025-01-31 and 2026-11-04, split-adjusted, recomputed daily. Percentiles are against MAZE's own 2-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of MAZE's sector?
Maze Therapeutics, Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, MAZE ranks 7th of 15 tracked industries, weakening.
- Sector rank
- #1 of 12
- Sector state
- Weakening
- Sector rotation score
- 100
- Industry rank
- #7 of 15
Analyst Consensus Estimates
What do analysts expect MAZE to earn?
Analysts expect Maze Therapeutics, Inc. to earn -$2.73 per share in the fiscal year ending Dec 2026 and -$2.98 in the fiscal year ending Dec 2029, from 3 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Analyst Rating Changes
Are analysts turning bullish or bearish on MAZE?
Canaccord Genuity most recently initiated coverage on Maze Therapeutics, Inc. to Buy on Oct 19, 2026 with a price target of $75. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Canaccord Genuity: Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Corporate Stakes
Which companies own a stake in MAZE?
Alphabet Inc. reports a stake in Maze Therapeutics, Inc. on SEC Form 13F: 1.4M shares, about 2.57% of the company, worth $41.4M at the end of Q2 2026. At today's price that stake is worth $47.9M, about 0.00% of GOOGL's own market value.
- Holder
- GOOGL
- Shares held
- 1.4M
- Stake
- 2.57%
- Value
- $41.4M
| Holder | Last quarter | Shares | % of MAZE | Value at filing | Value now | Change |
|---|---|---|---|---|---|---|
| Alphabet Inc. GOOGL | 1.4M | 2.57% | $41.4M | $47.9M | +15.6% |
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
Earnings Release, Scored
What did Maze Therapeutics, Inc.'s latest earnings release say?
Most important lines
- 1
Net Loss: Net loss for the three and six months ended June 30, 2026 was $44.7 million, or $0.76 per share, and $68.9 million, or $1.22 per share, respectively, compared to net loss of $33.7 million, or $0.77 per share, and $66.5 million, or $1.83 per share, for the same periods in 2025.
New this quarterNegative tone - 2
We are also advancing MZE782 toward a Phase 2 trial in CKD, which we expect to initiate in the first half of next year.
New this quarter - 3
The increase primarily reflects higher expenses related to the progression of our clinical development of the MZE829 program and higher personnel-related costs, including non-cash stock-based compensation expense.
ETF holders
ETFs holding MAZE
Top ETF holdersWeight
News & sentiment
What is the news saying about MAZE?
MAZE rose 30.5% over the month to Nov 6. News tone held between 42 and 99 from Oct 6 to Nov 3, then jumped to 80 on Nov 4.
- Oct 19 +7.7%same day: How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
- Oct 20 +10.4%
- Nov 3 +6.2%same day: Maze Therapeutics to Participate in Upcoming Investor Conferences
Technical analysis
How strong is MAZE's momentum right now?
On the daily chart MAZE ranks at the 20th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling MAZE?
43 of the 60 tracked managers added to MAZE in their latest 13F and 13 trimmed. Together they own 15.5% of the company, worth $248.4M. Vanguard Capital Management and State Street alone hold 5.1%.
- $53.1M positionAdded 23.9% last quarter
- 2State Street Corp1.84%$29.8M positionAdded 56.7% last quarter
- $28.5M positionAdded 50.1% last quarter
- 4Woodline Partners LP1.36%$22.0M positionAdded 13.2% last quarter
- $11.7M positionAdded 101.0% last quarter
- 6Aberdeen Group plc0.71%$11.5M positionAdded 69.6% last quarter
- 7Candriam S.C.A.0.51%$7.5M positionUnchanged last quarter
- $8.1M positionAdded 261.9K shares last quarter
- $7.8M positionAdded 39.8% last quarter
- 10Ameriprise Financial Inc0.42%$6.8M positionAdded 111.6% last quarter
Discover more
How has MAZE done against its peers?
Over the six months to Nov 6, MAZE returned +30.4%. Of the 15 related stocks and ETFs, 6 did better, led by MRNA at +424.4%.
- 1MRNAModerna, Inc.up 424.4%+394.0 pts
- 2ARKGARK Genomic Revolution ETFup 46.5%+16.1 pts
- 3AMGNAmgen Inc.up 39.4%+9.0 pts
- 4ROIVRoivant Sciences Ltd.up 37.2%+6.8 pts
- 5RPRXRoyalty Pharma plcup 34.6%+4.3 pts
- 6BIIBBiogen Inc.up 30.6%+0.2 pts
- 7MAZEThis stockup 30.4%
- 8RVMDRevolution Medicines, Inc.up 29.2%−1.2 pts
- 16INSMInsmed Incorporateddown 20.3%−50.7 pts
